Alpine Immune Sciences logo
Alpine Immune Sciences ALPN
report update icon

Quarterly report 2024-Q1
added 06-06-2026

Alpine Immune Sciences Revenue | ALPN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Alpine Immune Sciences

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
58.9 M 30.1 M 23.4 M 9.34 M 1.74 M 705 K 1.73 M 2.95 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
58.9 M 705 K 16.1 M

Quarterly Revenue Alpine Immune Sciences

2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
7.03 M - 10 M 8.59 M 9.39 M - 8.37 M 5.29 M 13.6 M - 8.52 M 7.19 M 3.2 M - 1.91 M 688 K 1.09 M - 289 K 567 K - - - 390 K 315 K - 128 K - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
13.6 M 128 K 4.81 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
MacroGenics MacroGenics
MGNX
150 M $ 1.97 -0.76 % $ 124 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
46 M $ 121.72 -2.2 % $ 7.74 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
309 B $ 37.8 -2.82 % $ 168 B danmarkDanmark
Marker Therapeutics Marker Therapeutics
MRKR
3.55 M $ 1.1 -17.05 % $ 16.8 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
247 M $ 15.62 -1.01 % $ 1.68 B usaUSA
NextCure NextCure
NXTC
22.4 M $ 6.62 -2.43 % $ 35.2 M usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
3.18 B $ 553.08 -1.08 % $ 24.5 B usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
39.2 M $ 115.19 -3.52 % $ 9.73 B usaUSA
Oragenics Oragenics
OGEN
37.7 K $ 0.16 -6.16 % $ 345 K usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
7.25 M $ 2.2 -5.98 % $ 286 M usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
15.4 M $ 16.11 1.26 % $ 2.76 B usaUSA
Precigen Precigen
PGEN
9.68 M $ 4.21 1.08 % $ 1.32 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
18.8 M $ 6.94 -0.57 % $ 956 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
4.36 K $ 0.66 -7.55 % $ 3.95 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
8.55 M $ 300.01 -3.5 % $ 6.75 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
12.1 M $ 3.22 -1.08 % $ 248 M usaUSA
Ocular Therapeutix Ocular Therapeutix
OCUL
52 M $ 5.57 -5.03 % $ 1.04 B usaUSA
Outlook Therapeutics Outlook Therapeutics
OTLK
1.41 M $ 0.39 -2.79 % $ 13.6 M usaUSA
uniQure N.V. uniQure N.V.
QURE
16.1 M $ 19.32 -4.5 % $ 1.11 B niderlandNiderland
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
673 M $ 16.46 -4.41 % $ 1.62 B usaUSA
Rafael Holdings Rafael Holdings
RFL
874 K $ 0.94 5.89 % $ 48.3 M usaUSA
REGENXBIO REGENXBIO
RGNX
170 M $ 7.16 -0.35 % $ 369 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
294 M $ 40.05 -2.78 % $ 720 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
500 K - -6.63 % $ 13.9 M usaUSA
I-Mab I-Mab
IMAB
27.6 M - - $ 866 M chinaChina
Tenax Therapeutics Tenax Therapeutics
TENX
49.3 K $ 1.27 -8.27 % $ 49.8 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
6.07 B - - $ 40.3 B usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
12 B $ 514.68 -1.15 % $ 132 B usaUSA
Genfit SA Genfit SA
GNFT
70.9 M - 2.54 % $ 160 B franceFrance
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
1 M $ 13.67 -8.01 % $ 1.49 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
48.9 M - - $ 867 M germanyGermany
Abcam plc Abcam plc
ABCM
362 M - - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
381 K - -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
-82 K $ 0.63 -7.05 % $ 67.2 M britainBritain
MorphoSys AG MorphoSys AG
MOR
238 M - 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
8.28 M - -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
12 M - -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
5 K - - $ 12.5 M belgiumBelgium